Anika Therapeutics (ANIK) Retained Earnings (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Retained Earnings data on file, last reported at -$5.3 million in Q1 2026.

• On a quarterly basis, Retained Earnings rose 12.99% year-over-year to -$5.3 million in Q1 2026; TTM through Mar 2026 was -$5.3 million, a 12.99% increase from a year earlier, with the FY2025 full-year figure at $60.8 million, down 15.18% from the prior year.
• Retained Earnings for Q1 2026 stood at -$5.3 million, down from $60.8 million in the prior quarter.
• Over the last five years, Retained Earnings for ANIK reached as high as $222.6 million in Q1 2022 and fell as low as -$7.5 million in Q3 2022.
• Historically, Retained Earnings has averaged $77.6 million across 5 years, with a median of $62.8 million in 2025.
• Across the five-year window, Retained Earnings surged 4507.94% in 2022 and sank 105.28% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $210.7 million in 2022, then slumped by 39.23% to $128.1 million in 2023, then slumped by 44.03% to $71.7 million in 2024, then fell by 15.18% to $60.8 million in 2025, then slumped by 108.74% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$5.3 million in Q1 2026, $60.8 million in Q4 2025, and -$4.9 million in Q3 2025.